Week 216 Review - Optibiotix drops yet again

Another bad week with OPTI:Optibiotix falling another 4p which costs £4,000 to my portfolio. Thankfully a good week for IQE:IQE and SBTX:SkinBioTherapeutics meant that the loss was reduced to £2,770. That extends the deficit between cost and value to £39,207 and reduced the portfolio value to £64,907.

OPTI:Optibiotix was the only significant faller, but they dropped 6% and my holding is now 35% down. That's about £20,000

IQE:IQE had a good week with the SIPP climbing 7%, the trading account climbing 8% and the ISA climbing 11% of the purchase price. The ISA is only 15% down now, so looking slightly less horrific.

Share of the Week is SBTX:SkinBioTherapeutics, with the ISA holding climbing 18% and the SIPP climbing 25% on anticipation of an impending big deal.

Back below the injection line

Not quite as bad as 3 weeks ago, but almost

The ISA amd share portfolios look like this

			Weekly Change
Cash	£6.36		+£0
Portfolio cost	£57,768.95		+£0
Portfolio sell value (bid price-commission)	£33,749.94	(-41.6%)	-£1,713.64
Potential profits	£0		+£0
Yr 5 Dividends	£0		+£0
Yr 5 Profit from sales	£-167.28		+£0
Yr 5 Average monthly cash profit	-£92.64	(-1.9%)	+£13.24
Total Dividends	£1,342.30		+£0
Total Profit from sales	£20,224.13		+£0
Average monthly cash profit	£428.74	(8.9%)	-£2.00
(Sold stocks profit + Dividends - Fees  / Months)

Down again and all thanks to OPTI:Optibiotix

Here's the SIPP after week 200

			Weekly Change
Cash	£17.96		+£0
Portfolio cost	£43,965.42		+£0
Portfolio sell value (bid price - commission)	£29,801.35	(-32.2%)	-£1,062.33
Potential profits	£678.48		+£450.51
Yr 4 Dividends	£361.99		+£0
Yr 4 Interest	£0.10		+£0
Yr 4 Profit from sales	£1,161.95		+£0
Yr 4 Average monthly cash profit	£136.87	(3.7%)	-£3.18
Total Dividends	£1,704.24		+£0
Total Interest	£0.13		+£0
Total Profit from sales	£11,706.87		+£0
Average monthly cash profit	£281.56	(7.7%)	-£1.41
(Sold stocks profit + Dividends - Fees / Months)

Same story as above, but the losses reduced by a decent increase in SBTX:SkinBioTherapeutics.

Just about staying the right side of the orange line

Way below the trend line

The trading portfolio looks like this after week 166

			Weekly Change
Cash	£35.04		+£0
Portfolio cost	£2,321.29		+£0
Portfolio sell value (bid price - commission)	£1,296.95	(-44.1%)	+£5.41
Potential profits	£0		+£0
Year 4 Dividends	£0		+£0
Year 4 Profit	£0		+£0
Yr 4 Average monthly cash profit	£0	(0%)	+£0
Dividends	£34.72		+£0
Profit from sales	-£64.29		+£0
Average monthly cash profit	-£0.77	(-0.4%)	+£0.01
(Sold stocks profit + Dividends - Fees  / Months)

Tiny rise from climb in IQE:IQE offset by drops in everything else.

Just the right side of the trend line

That's it. Late this week due to a weekend in North Norfolk. I'm not going to mention the horror that unfolded at MTFB:Motif Bio today as that's far too depressing.

Week 215 Review - Central Asia Metals recovery

I guess after the last few months I should be relieved when not much happens, although I was hoping for a steady recovery after the summer doldrums. Things were looking great after Thursday, with the combined portfolios up by over £3,000, but Friday was a disaster and all that was wiped out to finish £107 worse off. The deficit between cost and value is £36,436 and total portfolio value £67,618.

There were no significant losers this week, although OPTI:Optibiotix dropped 1p which cost me £1,000. It's great news that I only ended up £107 down considering that.

JLP:Jubilee Metals is starting to nudge higher as Kabwe progress is looking good. They climbed 7% but are still down by 29% overall.

Share of the Week is CAML:Central Asia Metals which had great interim results and held the dividend despite industrial metals prices being really low. They responded by climbing 9% which took them back into profit and 4% up. So glad I sold 40% of my holding to buy OPTI:Optibiotix and SBTX:SkinBioTherapeutics which have stayed flat since I bought them. I very rarely seem to time anything right.

Only just above the orange line by a few hundred quid. The mountain caused by OPTI:Optibiotix climbing to 134p just over a year ago has well and truly left the chart

Here's the ISA and share accounts

			Weekly Change
Cash	£6.36		+£0
Portfolio cost	£57,768.95		+£0
Portfolio sell value (bid price-commission)	£35,463.58	(-38.6%)	-£254.77
Potential profits	£0		+£0
Yr 5 Dividends	£0		+£0
Yr 5 Profit from sales	£-167.28		+£0
Yr 5 Average monthly cash profit	-£105.88	(-2.2%)	+£17.64
Total Dividends	£1,342.30		+£0
Total Profit from sales	£20,224.13		+£0
Average monthly cash profit	£430.74	(8.9%)	-£2.01
(Sold stocks profit + Dividends - Fees  / Months)

Most of the damage done by OPTI:Optibiotix falling 1p but mitigated by the rise in JLP:Jubilee Metals. Not enough to prevent a drop though. Average profit drops below 9% but there's nothing available to sell in order to improve it.

Still below the cash injection line so still utterly dire.

It needs £10,000 just to get up to the declining trend line, so really in a desperate state.

The SIPP looks like this after week 199

			Weekly Change
Cash	£17.96		+£0
Portfolio cost	£43,965.42		+£0
Portfolio sell value (bid price - commission)	£30,863.68	(-29.8%)	+£132.76
Potential profits	£227.97		+£227.97
Yr 4 Dividends	£361.99		+£0
Yr 4 Interest	£0.10		+£0
Yr 4 Profit from sales	£1,161.95		+£0
Yr 4 Average monthly cash profit	£140.05	(3.8%)	-£3.34
Total Dividends	£1,704.24		+£0
Total Interest	£0.13		+£0
Total Profit from sales	£11,706.87		+£0
Average monthly cash profit	£282.97	(7.7%)	-£1.43
(Sold stocks profit + Dividends - Fees / Months)

The good rise in CAML:Central Asia Metals overcame the OPTI:Optibiotix drop and also means there is a potential profit to record. Average performance down to 7.7% so well below target 10%, but at the moment I'm more concerned about paper value being 30% down on purchase price.

This account was in the black for a long, long time. Now I'm celebrating the fact it's just above the cash injection value.

As with the ISA, this account is on a similar trajectory of decline, but needs about £7,000 to get back above the trend line

The trading account looks like this after week 165

			Weekly Change
Cash	£35.04		+£0
Portfolio cost	£2,321.29		+£0
Portfolio sell value (bid price - commission)	£1,291.54	(-44.4%)	+£14.32
Potential profits	£0		+£0
Year 4 Dividends	£0		+£0
Year 4 Profit	£0		+£0
Yr 4 Average monthly cash profit	£0	(0%)	+£0
Dividends	£34.72		+£0
Profit from sales	-£64.29		+£0
Average monthly cash profit	-£0.78	(-0.4%)	+£0
(Sold stocks profit + Dividends - Fees  / Months)

The rise in CAML:Central Asia Metals and a small rise in IQE:IQE were enough to keep the drops in TEK:Tekcapital and TRMR:Tremor pulling it into the red for the week. How quickly will the 19% deficit be made up by CAML? Hopefully not before the dividend ex-date in October as I may as well get that. Broker target is 310p which would give me 24% profit. My target is a more modest 290p (16%) which will put the account into the black on average performance.

We're above the trend line! I'm not overly optimistic about the short term prospects though. Long term reasonably happy, but this isn't meant to be a long term account.

Here's my efforts in the fantasy share game

An excellent week, climbing 751 places from 1,542nd to 791st. Unfortunately this is the last week and the game has closed. Not sure if that's it, but I'll try again if they launch a new one. I finally sussed out the rules. Your performance is taken on the average of each of your percentage gains or losses. So if you sell a share, you bank the percentage gain, and if you sell one that's losing, you take a hit but prevent that percentage getting bigger. I hope they do launch a new one as I think I've got the hang of it now.

Nearly all the shares improved this week, particularly CAML:Central Asia Metals, so it was a nice end and explains my leap up the league as the shares that are up are up much more than the shares that are down.

MMX:Minds + Machines should be reporting interims on Tuesday as they have an analyst presentation booked. I'm hoping this will give the price a lift. My initial thought is that I'll get rid as soon as I can, but a lot depends on how bullish the interims are. There is potential for a low cost high revenue dividend-paying company here. They were cash rich but spent it acquiring a company, which is good if that proves to be bringing in revenues.

TRMR:Tremor are also due to give interims on Tuesday. I really haven't a clue what to expect from them, but it's unlikely to make much of an improvement in the 50% decline since I bought them. We can but hope.  All will be revealed on Tuesday...

Week 214 Review - Small bounce back but will it last?

There was a mini recovery this week, with OPTI:Optibiotix clawing back some losses along with IQE:IQE. This lifted the portfolio value by £4,289 and reduced the deficit to £36,329. There's a long way to go, but the portfolio value of £67,785 is at least slightly higher than the amount of cash I've put in.

No shares fell by more than 5% this week, possibly for the first time ever.

OPTI:Optibiotix climbed 4p, which is 6% of the purchase price and accounted for £4,000 of this week's rise. Nice and easy to calculate since I got to 100,000 shares.

Share of the Week goes to IQE:IQE which also climbed 6%, but OPTI is in the doghouse and doesn't deserve a prize so IQE gets it.

The green line is just above the orange, and it had better stay there!

Still a long way to go before the downward trend can be reversed.

The ISA and share accounts look like this

			Weekly Change
Cash	£6.36		+£0
Portfolio cost	£57,768.95		+£0
Portfolio sell value (bid price-commission)	£35,718.35	(-38.2%)	+£2,405.02
Potential profits	£0		+£0
Yr 5 Dividends	£0		+£0
Yr 5 Profit from sales	£-167.28		+£0
Yr 5 Average monthly cash profit	-£148.23	(-2.6%)	+£24.71
Total Dividends	£1,342.30		+£0
Total Profit from sales	£20,224.13		+£0
Average monthly cash profit	£432.75	(9.0%)	-£2.03
(Sold stocks profit + Dividends - Fees  / Months)

A nice increase, but it's not as much as last week's drop in value, so the climb is possibly going to take longer than the drop.

Still below the injection amount.

As with the overall chart, a long way to go just to continue the steady decline, and even further to reduce it.

The SIPP looks like this after week 198

			Weekly Change
Cash	£17.96		+£0
Portfolio cost	£43,965.42		+£0
Portfolio sell value (bid price - commission)	£30,730.92	(-30.1%)	+£1,865.00
Potential profits	£0		+£0
Yr 4 Dividends	£361.99		+£0
Yr 4 Interest	£0.10		+£0
Yr 4 Profit from sales	£1,161.95		+£0
Yr 4 Average monthly cash profit	£143.39	(3.9%)	-£3.49
Total Dividends	£1,704.24		+£0
Total Interest	£0.13		+£0
Total Profit from sales	£11,706.87		+£0
Average monthly cash profit	£284.40	(7.8%)	-£1.44
(Sold stocks profit + Dividends - Fees / Months)

Similar story to the ISA, with the rise smaller than last week's loss, but a rise is still a good thing.

If this had crossed the injection line I would have been terribly vexed.

Same story as the other performance charts

The trading account looks like this after week 164

			Weekly Change
Cash	£35.04		+£0
Portfolio cost	£2,321.29		+£0
Portfolio sell value (bid price - commission)	£1,277.22	(-45.0%)	+£19.05
Potential profits	£0		+£0
Year 4 Dividends	£0		+£0
Year 4 Profit	£0		+£0
Yr 4 Average monthly cash profit	£0	(0%)	+£0
Dividends	£34.72		+£0
Profit from sales	-£64.29		+£0
Average monthly cash profit	-£0.78	(-0.4%)	+£0.01
(Sold stocks profit + Dividends - Fees  / Months)

Once again, the rise was less than last week's fall. Bad news for getting rid of TALY:Tally as they are not likely to re-list until May 2020. The nearest to profit is CAML:Central Asia Metals which is 26% down. Nothing is likely to move from this account for a while yet.

Kissing the trend line once again. Just need to get above it.

Here's the latest fantasy stock position

I've dropped 461 places to 1,542nd. I think I need to read the rules properly as this is a bit rubbish

Not sure what's going on at CEY:Centamin. They should be about 25% up but seem to have plummeted over the last 2 weeks and are now lower than when I sold my holdings. This game has proved useful else I would have missed that. I can keep an eye out for an opportunity to buy back in.

Such a relief to have one week without the despair that has set in for the last few months. It may end up being a blip, but today is St Leger Day so will we see some buying on Monday, or will the continued anxiety around Brexit and US/China trade wars drag us down?

Week 213 review - Biggest ever losses but I'm happy

Normally losing £4,782 portfolio value in a week would seem really, really bad, especially when it also means the deficit between cost and value is bigger than it has ever been at £40,618, but after last week it doesn't seem so bad. The portfolio is now worth £63,496 which is about £4,000 less than the money I've put in. The mattress would have been a better option!

That should be enough to have me leaping off a skyscraper, but strangely I'm feeling really happy, as the (temporary) crash in value has given me an opportunity I never thought I would have. I'm almost shocked into disbelief that I now own over 100,000 shares in OPTI:Optibiotix. That's beyond my wildest dreams, and if all goes to plan should ensure I can retire early. Granted, the reason I have so many is that I took a loss in order to buy them in a fire sale, but with at least eight significant announcements due over the next few months, I had to get some more.

There was very little movement in any of my shares this week, but OPTI:Optibiotix was by far the worst, crashing 8% when it dropped 5p. Now I have my extra shares, each penny change in share price is worth £1,000 so it's going to be a hell of a ride one way or another.

Not far behind OPTI, SBTX:SkinBioTherapeutics fell 5% in sympathy. That triggered another bargain hunt as I bought about 16,000 at 14p. When the news of a deal with a multi-national comes out, then we should see a re-rate. It also makes me feel a bit less worried about trading the ones in my ISA, as I know I have my SIPP holding long term.

Only one share had anything like a significant rise this week and is Share of the Week. TLOU:Tlou Energy has been very slowly sneaking up each day, so by the end of the week had climbed 7%. It's still 43% down, but there's hope for the long-awaited re-rate.

That's it, the SIPP can no longer hold the combined accounts above the injection line. I'm now worse off than if I hadn't bothered investing anything. I prefer to think I have £104K worth of assets that are just on hard times at the moment.One thing's for sure - this chart is going to look dramatic for the next 12 months until that cliff-face vanishes off the left hand side.

It is a relentless decline in value finally slipping over a cliff.

The ISA and share portfolios look like this

		Weekly Change
Cash	£6.36		-£3.75
Portfolio cost	£57,768.95		+£0
Portfolio sell value (bid price-commission)	£33,313.33	(-42.3%)	-£2,749.28
Potential profits	£0		+£0
Yr 5 Dividends	£0		+£0
Yr 5 Profit from sales	£-167.28		+£0
Yr 5 Average monthly cash profit	-£148.23	(-3.1%)	+£32.99
Total Dividends	£1,342.30		+£0
Total Profit from sales	£20,224.13		+£0
Average monthly cash profit	£434.78	(9.0%)	-£2.13
(Sold stocks profit + Dividends - Fees  / Months)

Big slump in value. Average performance still good, and average annual performance improving as each week that's not negative results in a smaller average monthly loss

Well below the injection line now

The SIPP looks like this after week 197

			Weekly Change
Cash	£19.96		-£17.57
Portfolio cost	£43,965.42		-£261.07
Portfolio sell value (bid price - commission)	£28,865.92	(-34.3%)	-£2,273.95
Potential profits	£0		+£0
Yr 4 Dividends	£361.99		+£0
Yr 4 Interest	£0.10		+£0
Yr 4 Profit from sales	£1,161.95		-£278.48
Yr 4 Average monthly cash profit	£146.88	(4.0%)	-£35.16
Total Dividends	£1,704.24		+£0
Total Interest	£0.13		+£0
Total Profit from sales	£11,706.87		-£278.48
Average monthly cash profit	£285.84	(7.8%)	-£7.89
(Sold stocks profit + Dividends - Fees / Months)

A sea of red. I took a £278 loss selling CAML:Central Asia Metals in order to get my 100,000th OPTI:Optibiotix share and finally get a decent stake in SBTX:SkinBioTherapeutcs. The re-invested money meant the cost of the portfolio dropped by £261. The loss also hammered my year 4 average performance and even my long term performance took a  0.2% hit as a result of the sale at a loss. My reasoning is that metals will be priced low for a while yet, whereas both OPTI and SBTX are likely to surge as they have in the past, so I should have a longer opportunity to build my stage back in CAML.

Still just above the orange line!

So, so bad.

The trading account looks like this after week 163

			Weekly Change
Cash	£35.04		+£0
Portfolio cost	£2,321.29		+£0
Portfolio sell value (bid price - commission)	£1,258.17	(-45.8%)	-£19.91
Potential profits	£0		+£0
Year 4 Dividends	£0		+£0
Year 4 Profit	£0		+£0
Yr 4 Average monthly cash profit	£0	(0%)	+£0
Dividends	£34.72		+£0
Profit from sales	-£64.29		+£0
Average monthly cash profit	-£0.79	(-0.4%)	+£0
(Sold stocks profit + Dividends - Fees  / Months)

A small dip but nothing remotely exciting.

Love the way it's following the trend line. Actually, scrub that last comment because I don't love it at all, I'm deeply concerned by it.

I've crashed down the fantasy league from 769th to 1,081st which is 312 places.

Still don't properly understand how it works!

That's it for another miserable week, but one where I end with a smile on my face. I'm now going to watch England play footie and then do a double blu-ray evening of Avengers Infinity War and Avengers Endgame now I've finally been able to get it. Avoiding spoilers for 6 months has been tricky!

Optibiotix holding reaches 100,000 shares

There was never an ambition to get to 100,000 OPTI:Optibiotix shares until recently. I think it was when I passed 90,000 the glimmer of that idea started to form. There's no way I would have done it without the absolute fire sale that's going on at the moment though.

When OPTI went back to 46p, and when I saw SBTX:SkinBioTherapeutics being hammered almost in sympathy, I decided the potential rewards for getting in at these prices were worth some sacrifice.

It was a painful sacrifice, as I've been building a position in CAML:Central Asia Metals for a long time, and it's the best run company in my portfolio. However, looking at old purchases I realised that if I had kept each purchase on a separate line in my spreadsheet, about 2,000 shares worth would be in profit now.

So although on paper I made a loss of £278.48 (6.9%) by selling them now, that's only because my paper losses on the remaining shares would be significantly greater without the ones purchased at a much lower price.

That's how I justified the sale to myself anyway.

I also offloaded all the commission charges for buying the shares onto today's sale, so the remaining 3,000 are free of purchase commission when judging performance.

This liberated £3,776 as ammo for OPTI and SBTX.

I only wanted to get just over the 100,000 target for OPTI:Optibiotix shares, so bought 3,000 at 46p costing £1,391.95. This brings the weighted average in my SIPP down to 66.4p.

Where does this leave me overall?

I have 100,023 shares costing £66,196.14 at a weighted average of 66.18p if you include all the commission charges. Unfortunately they are only worth £42,974.04 so are losing £23,222.10 (35%). That's really, really painful, but I still believe this is short term pain, as there's nothing that has changed my outlook and excitement about being part of this company.

I've wanted to increase my holding in SBTX:SkinBioTherapeutics for a while, as despite already owning a good chunk courtesy of my OPTI:Optibiotix shares, it's likely those will be converted to a cash dividend at some point, and SBTX may be too expensive to buy by then.

I managed to snap up 16,983 at 14p costing £2,389.57 with commission.

I'll keep a tight hold of these, as I'm convinced they will become profitable as soon as this blip passes, and given we're expecting news of a deal soon, they could rapidly increase in value. I'll aim to trade my ISA holding on peaks and troughs, as that's only 7,285 shares and I'll feel more able to risk being out and missing a surge if I still have a long term holding. The ISA shares cost me 19.5p and are 32% down, so it will be a wait till I can sell them. More evidence that I'm crap at trading!

The week is continuing my portfolio misery, with a drop of £5,937 so far. That's enough to cross the combined cash injection line so is utterly disastrous. All I can do is hold on and wait. I've made all my moves and some painful sacrifices, so let's see if it was worthwhile...

Week 212 Review - Utterly catastrophic collapse

What an utterly desperate, miserable, soul-destroying week. A complete lack of understanding from shareholders and the market caused the OPTI:Optibiotix share price to plummet when the H1 results were announced, despite year on year income being almost double H1 last year. When licence payments and royalties are paid annually and most of them occur in H2, you can't compare H1 this year with H2 last year!

As a result of the panic selling, my portfolio lost £15,563 in about an hour and the deficit has widened to £35,836, with overall portfolio about half of what it was last year at £68,561

Biggest and most spectacular loser was OPTI:Optibiotix dropping 17p which is 24%. I did manage to scoop up some more at around 47p on results day after selling AMYT:Amryt Pharma for a small loss. I wish just one of my other shares was in profit as I would have sold them to take advantage of this, but I already did that with my badly timed sale of CEY:Centamin when OPTI were still 67p.

TRMR:Tremor yo-yos by about 7% a week so it was no surprise they dropped 7% this week and are now 52% down on when I bought them.

SBTX:SkinBioTherapeutics suffered inexplicably from OPTI dropping and were a bargain mid-week, but clawed back much of the looses and ended up 6% down. That means my holding is 27% down which is grim given I thought I'd bought them at the bottom of their trading range.

IQE:IQE continue to suffer and were down 5% this week, which is expensive as they are one of my larger holdings.

There were only three shares that increased in value this week, so I'm going to list them all to try and boost my morale.

CAML:Central Asia Metals climbed 2%, which means they are only 5% down now. Fortunately I've had so much in dividends that they are kind of 8% up, but that's small consolation. They were around 40% in profit at one point before the copper price collapse. Given they are such a low cost producer, I still don't understand why they get hammered so badly as they still pay a big dividend even when the copper price is low.

WRES:W Resources climbed a measly 3% given they completed their concentrator construction. My holding is 47% down, so even if they start producing and making a profit, I'm unlikely to be in the black for a long time as they have been massively diluted from placings since I bought them. I only bought £430 worth when I had some spare dividends and fancied a punt, so fairly relaxed.

Share of the Week is TEK:Tekcapital which managed to drag itself up by 5% but is still 47% down so I suspect this will be making a loss until they have enough cash to pay a dividend, which will probably be a decade.

There you go. The green line almost meets the cash injection line, so if I sold everything today I would have been better off putting it in the Building Society. However, I'm still happy that the value of my shares is such that this blip can't last, and given the volatility of OPTI:Optibiotix I wouldn't be surprised if the recovery wasn't swift and soon. It happened just over a year ago when we went from 56p to 134p in about a month. In those days we were a lot further away from revenues than we are now, with over £1 million a very realistic target for this year, and a dividend from the sale of SBTX:SkinBioTherapeutics not that far away.

Here's the performance of the ISA and share portfolios

			Weekly Change
Cash	£10.11		-£13.41
Portfolio cost	£57,768.95		-£153.87
Portfolio sell value (bid price-commission)	£36,062.61	(-37.6%)	-£9,123.51
Potential profits	£0		-£11.66
Yr 5 Dividends	£0		+£0
Yr 5 Profit from sales	£-167.28		-£167.28
Yr 5 Average monthly cash profit	-£181.22	(-3.8%)	-£181.22
Total Dividends	£1,342.30		+£0
Total Profit from sales	£20,224.13		-£167.28
Average monthly cash profit	£436.91	(9.1%)	-£5.50
(Sold stocks profit + Dividends - Fees  / Months)

A sea of red. The sale of AMYT:Amryt Pharma gave me a £167 loss, and it was the first sale of year 5 so the annual performance is negative. The hit on overall performance was very low, dropping from 9.2% to 9.1%. The most horrific figure is the £9,123 drop in value. Utterly shocking and it makes me miserable every time I look at it.

This one plunges below the injection line. I would have been better off leaving my cash under the mattress!

Ouch!

Here's the SIPP after week 196

			Weekly Change
Cash	£35.53		+£20.01
Portfolio cost	£44,226.49		+£0
Portfolio sell value (bid price - commission)	£31,139.87	(-29.6%)	-£6,572.36
Potential profits	£0		+£0
Yr 4 Dividends	£361.99		+£0
Yr 4 Interest	£0.10		+£0.01
Yr 4 Profit from sales	£1,440.43		+£0
Yr 4 Average monthly cash profit	£182.04	(4.9%)	-£4.66
Total Dividends	£1,704.24		+£0
Total Interest	£0.13		+£0.01
Total Profit from sales	£11,985.35		+£0
Average monthly cash profit	£293.73	(8.0%)	-£1.50
(Sold stocks profit + Dividends - Fees / Months)

Cash went up as I had to inject £20 to cover fees. I also got another 1p interest so there's some good news this week! Portfolio value crashed by £6,572 but overall performance stayed at 8%.

At least this one didn't drop to the injection level and is managing to keep my overall portfolios above the dreaded orange line.

Looks rather like a cliff face.

Here's the trading account after week 162

			Weekly Change
Cash	£35.04		+£0
Portfolio cost	£2,321.29		+£0
Portfolio sell value (bid price - commission)	£1,278.08	(-44.9%)	-£21.01
Potential profits	£0		+£0
Year 4 Dividends	£0		+£0
Year 4 Profit	£0		+£0
Yr 4 Average monthly cash profit	£0	(0%)	+£0
Dividends	£34.72		+£0
Profit from sales	-£64.29		+£0
Average monthly cash profit	-£0.79	(-0.4%)	+£0.01
(Sold stocks profit + Dividends - Fees  / Months)

A pretty flat week as this account is sheltered from the pains of OPTI:Optibiotix, but the 5% rise in TEK:Tekcapital wasn't enough to mitigate losses elsewhere.

A slow steady descent into oblivion.

It's now starting to follow the trend line exactly, which isn't good.

Here's the fantasy stock performance

I actually climbed 22 places this week from 791st to 769th.

I've not really had time to look at this properly. I still don't know if I chrystallise losses when I sell a losing company, let alone checking performance of other FTSE companies, but it's a bit of fun and a handy way of keeping an eye on some shares I may consider adding to my SIPP when I get my next £2,000 in November.

So, in a week when my football team got booted out of the league, I also had to watch my portfolio dive right back to the injection line and obliterate every penny of profit I've made over the last four years. I know that's not really the case, as I have the assets that cost me over £100K, but it feels that way.

On the positive side, I've increased my OPTI:Optibiotix holding to 97,000 shares and am still confident that will allow me to retire early no matter what the rest of the portfolio does. When CAML:Central Asia Metals recovers it will be swift, and I've significantly increased my holding there to 5,000 shares which will give me some hefty dividends. JLP:Jubilee Metals may finally be about to make some profits and a re-rate there should follow. SBTX:SkinBioTherapeutics will announce a major deal shortly and will rocket. IQE:IQE have dramatically increased production and that investment will pay off, and the shorters have been gradually closing their positions. TLOU:Tlou Energy are producing gas so it won't be too long before they are generating power.

With that lot there's plenty to be excited about. There's also my high-risk pot that are in the doldrums but which could come good. MTFB:Motif Bio probably have the best chance. They are 93% down, but once they show there's no liver toxicity with Iclaprim they could rapidly return to the original price. KIBO:Kibo Energy are still making progress. The market doesn't believe they will ever deliver which is why they are down 90%, but if they do then I can get out as I don't want to be investing in coal during a climate crisis! My ethics don't stretch to suffering a massive loss to get out now though.

I'm looking forward to next week, as it's hard to imagine how things could get any worse...